<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04975217</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0788</org_study_id>
    <secondary_id>NCI-2021-03484</secondary_id>
    <secondary_id>2020-0788</secondary_id>
    <nct_id>NCT04975217</nct_id>
  </id_info>
  <brief_title>Fecal Microbial Transplants for the Treatment of Pancreatic Cancer</brief_title>
  <official_title>Pilot Study Using Fecal Microbial Transplants in Patients With Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial examines the safety and effects of fecal microbial transplants in&#xD;
      treating patients with pancreatic cancer. scheduled for surgery to remove tumors. Fecal&#xD;
      microbial transplant contains the normal microbes found in fecal (stool) material. Giving&#xD;
      fecal microbial transplant may help control the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess the safety, tolerability, and feasibility of fecal microbiota transplantation&#xD;
      (FMT) in resectable patients with pancreatic ductal adenocarcinoma (PDAC).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess changes in gut microbiome of PDAC patients after FMT. II. To assess changes in&#xD;
      oral microbiome of PDAC patients after FMT. III. To assess changes in tumor microbiome of&#xD;
      PDAC patients after FMT. IV. To determine immunological/molecular changes in the tumor after&#xD;
      FMT.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo FMT during colonoscopy. Patients also receive FMT capsules orally (PO) once&#xD;
      weekly (QW) for 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients then undergo standard of care resection of tumor(s).&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 2 weeks and 30, 60, 90, and&#xD;
      180 days after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>Will be measured by Common Terminology Criteria for Adverse Events, version 5.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (FMT, FMT capsules)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo FMT during colonoscopy. Patients also receive FMT capsules PO QW for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care resection of tumor(s).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>Undergo FMT</description>
    <arm_group_label>Treatment (FMT, FMT capsules)</arm_group_label>
    <other_name>Fecal Material Transplantation</other_name>
    <other_name>Fecal Transplantation</other_name>
    <other_name>FMT</other_name>
    <other_name>Poo Transplant</other_name>
    <other_name>Poop Transplant</other_name>
    <other_name>Stool Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation Capsule</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (FMT, FMT capsules)</arm_group_label>
    <other_name>Fecal Microbiota Preparation Delivery Capsule</other_name>
    <other_name>FMPCapDE</other_name>
    <other_name>FMT Capsule DE</other_name>
    <other_name>FMT Capsule Delivery</other_name>
    <other_name>FMT DE Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (FMT, FMT capsules)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Resection</intervention_name>
    <description>Undergo standard of care resection</description>
    <arm_group_label>Treatment (FMT, FMT capsules)</arm_group_label>
    <other_name>Surgical Resection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Colonoscopy</intervention_name>
    <description>Undergo colonoscopy</description>
    <arm_group_label>Treatment (FMT, FMT capsules)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients that are seen at MD Anderson Cancer Center&#xD;
&#xD;
          -  Patients with pancreatic ductal adenocarcinoma (PDAC) diagnosis who are expected to&#xD;
             have surgery (whipple)&#xD;
&#xD;
          -  Patient should have normal levels of blood cell count (CBC) differential and CBC&#xD;
             chemistry test results&#xD;
&#xD;
          -  White blood cell (WBC) count &gt;= 3,000/microL&#xD;
&#xD;
          -  Platelet count &gt;= 75,000/microL&#xD;
&#xD;
          -  Hemoglobin (Hgb) &gt;= 8 g/dL&#xD;
&#xD;
          -  Total bilirubin level =&lt; 1.5 x the upper limit of normal (ULN)&#xD;
&#xD;
          -  An aspartate aminotransferase (AST) level =&lt; 2.5 x ULN&#xD;
&#xD;
          -  An alanine aminotransferase (ALT) level =&lt; 2.5 x ULN&#xD;
&#xD;
          -  Estimated creatinine clearance &gt; 30 mL/min according to the Cockcroft-Gault formula or&#xD;
             by a creatinine clearance measurement from a 24-hour urine collection&#xD;
&#xD;
          -  Between ages 18-70&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Willingness and ability to sign an informed consent&#xD;
&#xD;
          -  Consent and ability to give blood and stool samples&#xD;
&#xD;
          -  Consent to undergo a baseline core biopsy and colonoscopy for FMT delivery&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age younger than 18 years&#xD;
&#xD;
          -  Positive gastrointestinal (GI) infection&#xD;
&#xD;
          -  Patients with pancreatic cancer stage T1N0&#xD;
&#xD;
          -  Individuals at higher risk of colonization with multi-drug resistant organisms (MDROs)&#xD;
&#xD;
          -  Patient received antibiotics in the last 48 hours. Patients will be eligible to enroll&#xD;
             if antibiotic therapy is discontinued for at minimum 48 hours prior to start of study&#xD;
&#xD;
          -  Patients with active viral, bacterial or fungal infection&#xD;
&#xD;
          -  History of inflammatory bowel disease, and/or radiation enteritis or colitis&#xD;
&#xD;
          -  Pregnant and breastfeeding women&#xD;
&#xD;
          -  Women of child-bearing potential who have positive urine or serum pregnancy test or&#xD;
             refuse to do pregnancy test&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency&#xD;
&#xD;
          -  Peripheral WBC &gt; 12 x 10^9/L and/or temperature &gt; 38 degrees Celsius&#xD;
&#xD;
          -  Subjects with neutropenia (absolute neutrophil count [ANC] &lt; 1500)&#xD;
&#xD;
          -  Swallowing dysfunction or known chronic aspiration&#xD;
&#xD;
          -  Delayed gastric emptying&#xD;
&#xD;
          -  History of intestinal obstruction&#xD;
&#xD;
          -  Acute exacerbation of underlying comorbid condition&#xD;
&#xD;
          -  Severely immunocompromised patients&#xD;
&#xD;
          -  Allergies to ingredients generally recognized as safe&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florencia McAllister</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Florencia McAllister</last_name>
      <phone>713-563-4743</phone>
      <email>fmcallister@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Florencia McAllister</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

